Jump to content

Tofy Mussivand: Difference between revisions

From Wikipedia, the free encyclopedia
Content deleted Content added
No edit summary
No edit summary
Line 15: Line 15:
}}
}}


'''Tofy Mussivand''' ({{lang-fa|توفیق موسیوند}}, born c. 1943 in [[Varkaneh]], [[Hamadan Province]], [[Iran]]) is a [[Kurdish Iran]]ian-Canadian medical engineer.<ref name="ottawaheart">http://www.ottawaheart.ca/content_documents/Tofy-Mussivand-CV.pdf</ref>
'''Tofy Mussivand''' ({{Kurdish|ته وفیق موسیوه ند}}, born c. 1943 in [[Varkaneh]], [[Hamadan Province]], [[Iran]]) is a [[Kurdish Iran]]ian-Canadian medical engineer.<ref name="ottawaheart">http://www.ottawaheart.ca/content_documents/Tofy-Mussivand-CV.pdf</ref>


==Education ==
==Education ==

Revision as of 12:23, 31 January 2014

Tofy Mussivand
File:Toufymousivand.jpg
Born
NationalityKurdish Iranian-Canadian
OccupationEngineer
Known forthe invention of Artificial Cardiac Pump

Tofy Mussivand (Template:Kurdish, born c. 1943 in Varkaneh, Hamadan Province, Iran) is a Kurdish Iranian-Canadian medical engineer.[1]

Education

He studied engineering at Tehran University and University of Alberta.[1] Mussivand received his undergraduate education and training in engineering and management. Following many successful years in senior positions in Canadian government, crown corporations, and the private sector, Dr. Mussivand went on to receive his doctorate in Medical Engineering and Medical Sciences at the University of Akron and Northeastern Ohio Universities College of Medicine. Thereafter, Mussivand joined the Cleveland Clinic Hospital and Research Foundation where he gained knowledge and experience in the development of medical devices, artificial hearts, and cardiac care. In 1989, Mussivand was invited to return to Canada to continue his pioneering work in medical devices.

Inventions

Tofy Mussivand is known for the invention of Artificial Cardiac Pump. Cardiac pump or cardiac bypass pump or heart-lung machine temporarily takes over the function of breathing and pumping blood for a patient. It generally has two parts, the pump and the aerator. Cardiac pumps are most often used in heart surgery, so that a patient's heart can be disconnected from the body for longer than the twenty minutes or so it takes a prepared patient to die.

His breakthroughs have resulted in the establishment of scientific eminence for Canada in the fields of medical devices, artificial hearts, remote power transfer, in situ sterilization, etc.[2]

He is Professor of Surgery and Engineering at the University of Ottawa and Carleton University; Chair and Director, Cardiovascular Devices Division of the University of Ottawa Heart Institute (UOHI); and Medical Devices Program of both the University of Ottawa and Carleton University. He is an honorary member of Iranian Academy of Medical Sciences.

Mussivand has published over 250 papers, books, and technical articles and supervised and taught over 300 students, residents, and postdoctoral Fellows.

Selected publications

  • Mussivand, Tofy (2004). "856-1 Mechanical circulatory support: Evolving trends in support duration". Journal of the American College of Cardiology. 43.5:A233. Elsevier Biomedical. ISSN 0735-1097. OCLC 98570923.
  • Imachi, Kou; Mussivand, Tofy (2010). "Outline of the International Organization for Standardization Standard for Circulatory Support Devices (ISO 14708-5)". Artificial Organs. 34.9. Blackwell Publishing: 695–698. ISSN 1525-1594. OCLC 666863666.
  • Mussivand, Tofy (2003). "Honoring Living Legends". Artificial Organs. 27.6. Blackwell Science: 581–582. ISSN 1525-1594. OCLC 437591192.
  • Mielniczuk, Lisa; Mussivand, Tofy; Davies, Ross; Mesana, Thierry G (2004). "Patient Selection for Left Ventricular Assist Devices". Artificial Organs. 28.2. Blackwell Publishing: 152–157. ISSN 1525-1594. OCLC 437941681.
  • Mussivand, Tofy (1998). "Lessons Learned from the Grandfather of Artificial Organs". Artificial organs. 22.11. New York, Raven Press: 985. ISSN 1525-1594. OCLC 92216345.
  • Mussivand, Tofy (1999). "ORIGINAL ARTICLES - Mechanical Circulatory Devices for the Treatment of Heart Failure - The results of a prospective trial of partial left ventriculectomy (PLV) in patients with idiopathic dilated cardiomyopathy, left ventricular end-diastolic diameter (LVEDD) > 7 cm, refractory NYHA Class IV symptoms, and depressed exercise oxygen consumption studies are reported. PLV can be performed with acceptable early and 12-month mortality. Significant improvement in LVEF, LVEDD, and NYHA Class are seen at up to 12-month follow-up". Journal of cardiac surgery. 14 (3). Futura: 218. ISSN 0886-0440. OCLC 96424197.

References

Template:Persondata